December 19, 2023
Shionogi said on December 18 that it has launched a PIII booster trial in Japanese subjects for S-268023, a monovalent vaccine directed at the XBB1.5 strain of the novel coronavirus. The trial is a randomized, active controlled, double-blind program. It...read more